TY - ADVS
T1 - Adjuvant Treatment of Early-Stage Breast Cancer: T-DM1 Versus Paclitaxel Plus Trastuzumab
AU - Cutter, Noelle L
N1 - By: Noelle Cutter, PhD Posted: Tuesday, September 7, 2021 Adjuvant paclitaxel with trastuzumab is a common combination treatment for invasive early breast cancers with overexpression of HER2. In a phase II clinical trial, Sara M.
PY - 2021/9/7
Y1 - 2021/9/7
N2 - Adjuvant paclitaxel with trastuzumab is a common combination treatment for invasive early breast cancers with overexpression of HER2. In a phase II clinical trial, Sara M. Tolaney, MD, MPH, and colleagues from the Dana-Farber Cancer Institute, Boston, reported that 1 year of adjuvant therapy with trastuzumab emtansine (T-DM1) resulted in “excellent” invasive disease–free survival compared with paclitaxel plus trastuzumab but not a real difference in clinically relevant toxicities. Their results were reported in the Journal of Clinical Oncology.
AB - Adjuvant paclitaxel with trastuzumab is a common combination treatment for invasive early breast cancers with overexpression of HER2. In a phase II clinical trial, Sara M. Tolaney, MD, MPH, and colleagues from the Dana-Farber Cancer Institute, Boston, reported that 1 year of adjuvant therapy with trastuzumab emtansine (T-DM1) resulted in “excellent” invasive disease–free survival compared with paclitaxel plus trastuzumab but not a real difference in clinically relevant toxicities. Their results were reported in the Journal of Clinical Oncology.
UR - https://jnccn360.org/breast/medical-literature/adjuvant-treatment-of-early-stage-breast-cancer-t-dm1-versus-paclitaxel-plus-trastuzumab/
M3 - Web publication/site
ER -